Every 8-K that Amarin Corp Plc (AMRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMRN filings page.
Amarin Corporation plc reported Q2 2026 results with total net revenue of $42.2 million and a net loss of $7.7 million, compared with $72.7 million and a $14.1 million loss in Q2 2025. The revenue decline mainly reflects the absence of a $25 million upfront payment from the Recordati licensing agreement in the prior-year quarter, along with modest declines in U.S. and European product revenue amid generic competition and the shift to a partnered model.
Profitability metrics improved despite lower revenue. Operating expenses fell to $27.0 million, down 59% year over year, as a $70 million annual cost-savings program and restructuring tied to the Recordati partnership were completed, narrowing the operating loss to $12.0 million. Non-GAAP net income was $790 thousand. Cash reached $314.6 million at June 30, 2026, up from $302.6 million at December 31, 2025, and the company remained debt free while reducing inventories.
Operational trends were strong internationally and stable in the U.S. In-market demand for VASCEPA/VAZKEPA grew 59% across the global partner network, including 69% growth in Europe and 90% year-to-date growth in China. The U.S. IPE market share increased to 48% from 43%, VASCEPA prescriptions rose 14%, and management expects U.S. volumes to remain consistent in 2026 alongside continued international growth and positive cash flow generation.
Amarin Corporation plc reports that at its Annual General Meeting, shareholders re-elected all director nominees and approved the non-binding Say-on-Pay proposal, but several key capital and governance measures failed. Proposals to authorize the Board to issue shares up to a nominal £37,750,000, to increase the 2020 Stock Incentive Plan reserve by 15,000,000 Ordinary Shares, to disapply UK statutory pre-emption rights on up to £20,970,000 of share capital, and to permit electronic delivery of meeting materials were not approved. The Board states that, without these approvals, its ability to grant equity incentives to employees and directors is highly limited, so it expects most future annual incentive compensation to be paid in cash, which will affect the company’s total cash position. Amarin also expects to continue incurring printing and mailing costs for paper proxy materials. Turnout was substantial, with 295,122,317 Ordinary Shares, about 70% of the 419,458,656 shares entitled to vote as of the record date, present in person or by proxy.
Amarin Corporation reported Q1 2026 total net revenue of $45.1 million, up 7% from Q1 2025, driven by stable U.S. VASCEPA sales, higher rest-of-world product revenue, and an 84% increase in licensing and royalty revenue.
Total operating expenses fell 31% to $29.1 million, mainly from the June 2025 Global Restructuring and lower selling, general and administrative costs, which declined 42%. Operating loss narrowed to $11.3 million, and net loss improved to $10.5 million, or $(0.03) per ordinary share.
The company generated positive cash flow, with cash and investments rising to $307.8 million as of March 31, 2026, and remained debt free. On a non-GAAP basis, net loss was reduced to $1.8 million, reflecting add-backs for stock-based compensation, restructuring and a litigation settlement.
Amarin Corporation plc is reshaping its governance structure and updating how it pays non-employee directors. As part of an effort to follow what it views as best corporate governance practices, the board decided to reduce its size. On March 25, 2026, directors Paul Cohen and Oliver O’Connor chose not to stand for re-election at the 2026 annual meeting and will resign immediately before that meeting begins; their decisions are stated to be unrelated to any disagreement over operations, policies, or practices. The board will cut its size from nine to seven directors at that time.
The board also approved a revised non-employee director compensation policy. Each non-employee director is eligible for initial and annual equity awards of restricted stock units and options that vest in full on the earlier of one year after the grant date or the next annual meeting. These equity awards depend on shareholders approving both an issuance proposal and a pre-emption proposal at the 2026 annual meeting; if either fails, directors will not receive these equity awards and the board will consider alternative compensation such as cash.
Amarin Corporation plc reported fourth-quarter 2025 net revenue of $49.2 million, down 21% from a year earlier, but sharply narrowed its net loss to $1.2 million. Operating loss improved to $6.3 million from $52.5 million as restructuring and cost-cutting lowered expenses.
Product revenue declined across the U.S., Europe and Rest-of-World, while licensing and royalty revenue rose to $2.7 million. Amarin realized $31 million of an expected $70 million in restructuring-related cost savings and ended 2025 with $302.6 million in cash and investments and no debt.
For full-year 2025, net revenue was $213.6 million and GAAP net loss was $38.8 million, but non-GAAP adjusted net income reached $16.2 million. Management highlighted a return to positive cash flow in the fourth quarter and a long-term European licensing and supply agreement for VAZKEPA® with Recordati.
Amarin Corporation plc filed a current report to note that it has released a press release with its preliminary unaudited 2025 financial highlights. The release also summarizes key operational accomplishments for 2025 and outlines the company’s priorities for 2026. This information is being furnished as an exhibit rather than filed, which limits how it is incorporated into other regulatory documents.
Amarin Corporation plc furnished a Form 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025 and 2024.
The press release is included as Exhibit 99.1. The information is furnished under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act, except as specifically incorporated by reference in future filings.
Amarin Corporation plc appointed David Keenan, Ph.D., 58, as Executive Vice President and Chief Operating Officer, effective October 17, 2025. He previously served as EVP, Technical Operations and President of Europe, having joined Amarin in May 2022 to lead manufacturing, supply chain, technical operations, and quality.
The company stated there is no change to Dr. Keenan’s compensation with this appointment. Amarin also disclosed there are no arrangements or understandings tied to his selection, no family relationships with directors or executives, and no related party interests requiring disclosure.
Amarin Corporation plc (AMRN) filed an 8-K announcing two material events dated 20-24 June 2025.
1. Exclusive European license for VAZKEPA. On 20 June 2025 the company, through subsidiary Amarin Pharmaceuticals Ireland Limited, executed a 15-year license & supply agreement with Recordati Industria Chimica e Farmaceutica S.p.A. covering 59 European countries. Amarin will receive: (i) a $25 million upfront cash payment; (ii) up to $150 million in commercial milestone payments; and (iii) tiered royalties on Recordati’s net sales of VAZKEPA. The contract automatically renews for additional 15-year terms provided Recordati commercialises the product in at least one country before the initial term expires. Amarin retains full rights to VAZKEPA outside the licensed territory.
2. Global restructuring & cost reduction. On 24 June 2025 Amarin announced a restructuring programme, primarily focused on its European commercial operations. Management expects the initiative to trim annual operating expenses by roughly $70 million, with substantial completion targeted by 30 June 2026. The plan will trigger $30-$37 million in one-time charges, almost entirely cash outflows for termination benefits and related costs, to be recorded in Q2 2025 and largely paid by 31 December 2025. The company cautions that actual costs may differ materially from current estimates and that additional expenses could arise.
Strategic implications. The license immediately monetises European rights, provides non-dilutive capital, shifts commercial execution risk to Recordati, and maintains long-term participation through royalties. Simultaneously, the restructuring initiative reduces Amarin’s fixed cost base, potentially improving EBITDA break-even timelines. However, the company relinquishes direct control over a key geography and incurs material near-term cash charges. Future revenue visibility will depend on Recordati’s commercial success and milestone achievement.